Davis Todd C — SEC Form 4 filings
SEC reporting owner CIK 1392029. 23 Form 4 filings on record with FilingPulse; latest filed 2026-07-06.
Transaction summary — filings shown
Covers all 23 filings on record, filed 2024-02-16 to 2026-07-06. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 6 legs across 3 filings — 47,958 shares, $2,243,920 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 45.
- Largest priced transaction: purchase of 35,445 shares @ $27.80 ($985,534) in Pelthos Therapeutics Inc., filed 2026-06-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| LIGAND PHARMACEUTICALS INC (LGND) | Chief Executive Officer, Director | 13 | 4 legs · 12,010 sh · $1,243,937 | — | 30 |
| Pelthos Therapeutics Inc. (PTHS) | Director | 7 | 2 legs · 35,948 sh · $999,983 | — | 12 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | Director | 3 | — | — | 3 |
Form 4 filings — Davis Todd C
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-06 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Other (J): 132 @ $160.71 | EDGAR |
| 2026-06-15 | 4 | Pelthos Therapeutics Inc. (PTHS) | Purchase (P): 35,445 @ $27.80 · Purchase (P): 503 @ $28.73 | EDGAR |
| 2026-06-12 | 4 | PALVELLA THERAPEUTICS, INC. (PVLA) | Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4/A | Pelthos Therapeutics Inc. (PTHS) | Grant/award (A): 12,900 @ $0 · Grant/award (A): 4,961 @ $0 · Grant/award (A): 19,108 @ $0 | EDGAR |
| 2026-03-27 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 10,495 @ $0 · Grant/award (A): 50,058 (derivative) @ $0 | EDGAR |
| 2026-02-18 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 20,782 @ $0 · Tax withholding (F): 8,178 @ $183.83 · Grant/award (A): 39,644 @ $0 · Tax withholding (F): 15,600 @ $183.83 · Tax withholding (F): 2,039 @ $183.83 · Tax withholding (F): 4,255 @ $183.83 · +1 more | EDGAR |
| 2025-12-08 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Gift (G): 130 @ $0 | EDGAR |
| 2025-07-07 | 4 | Pelthos Therapeutics Inc. (PTHS) | Grant/award (A): 19,108 (derivative) · Grant/award (A): 58,230 (derivative) | EDGAR |
| 2025-07-03 | 4 | Pelthos Therapeutics Inc. (PTHS) | Conversion (C): 1,500,000 @ $10 · Conversion (C): 15,000 (derivative) @ $0 · Other (J): 31,278.68 (derivative) | EDGAR |
| 2025-07-02 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Other (J): 233 @ $91.08 | EDGAR |
| 2025-06-11 | 4 | PALVELLA THERAPEUTICS, INC. (PVLA) | Grant/award (A): 12,350 (derivative) @ $0 | EDGAR |
| 2025-05-13 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Purchase (P): 1,680 @ $104.57 · Purchase (P): 2,307 @ $104.53 · Purchase (P): 5,523 @ $105.67 | EDGAR |
| 2025-03-06 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 21,382 @ $0 · Grant/award (A): 93,476 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 20,784 @ $0 · Tax withholding (F): 6,966 @ $120 · Tax withholding (F): 2,231 @ $120 · Tax withholding (F): 4,255 @ $120 | EDGAR |
| 2024-12-17 | 4 | PALVELLA THERAPEUTICS, INC. (PVLA) | Grant/award (A): 24,700 (derivative) @ $0 | EDGAR |
| 2024-11-15 | 4 | Chromocell Therapeutics Corp (CHRO) | Grant/award (A): 49,605 (derivative) | EDGAR |
| 2024-08-09 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Purchase (P): 2,500 @ $97.39 | EDGAR |
| 2024-07-02 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Other (J): 350 @ $60.71 | EDGAR |
| 2024-06-18 | 4 | Chromocell Therapeutics Corp (CHRO) | Grant/award (A): 128,977 (derivative) | EDGAR |
| 2024-03-27 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Option exercise (M): 7,448 @ $46.20 · Option exercise (M): 2,855 @ $67.24 · Option exercise (M): 2,156 @ $68.51 · Option exercise (M): 3,556 @ $66.19 · Option exercise (M): 7,448 (derivative) @ $0 · Option exercise (M): 3,556 (derivative) @ $0 · +2 more | EDGAR |
| 2024-02-29 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 32,436 @ $0 · Grant/award (A): 131,723 (derivative) @ $0 | EDGAR |
| 2024-02-23 | 4 | Chromocell Therapeutics Corp (CHRO) | Option exercise (M): 29,167 @ $4.80 · Conversion (C) | EDGAR |
| 2024-02-16 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Tax withholding (F): 1,381 @ $74.65 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1392029 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →